Vascular reactivity in patients with heart failure, ex- and in vivo vasoresponsiveness

Completed

• Conditions: vasoplegia; 10019280; Heart failure

• Registration Number: NL-OMON55621
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

Group 1:
- Diagnosed with heart failure in line with the European Society of Cardiology
guidelines;
- Left ventricular ejection fraction <=<35%;
- Undergoing cardiac surgery on CPB., Group 2:
- Not diagnosed with heart failure;
- Left ventricular ejection fraction >50%;
- Undergoing cardiac surgery on CPB.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in the phase 1 of this study:
- Age <18 years;
- Incapacitated adults;
- Emergency operation;
- Patients in need of moderate of high dosages of intravenous inotropic support
(>4 gamma dobutamine or dopamine), vasopression and/or mechanical support;
- Patients with aortic valve insufficiency > grade 1;
- Patients using a daily dosage of nitroglycerine or isosorbide dinitrate;
- Patients using alpha blockers.
For phase 2, patients that meet any of the following criteria will be excluded
from the study:
- Age <18 years;
- Incapacitated adults;
- Emergency operation;
- Patients in need of moderate or high dosages of intravenous inotropic support
(>4 gamma dobutamine or dopamine) and/or vasopression;
- Patients using a daily dosage of nitroglycerine or isosorbide dinitrate;
- Patients using alpha blockers.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Change in SVR after phenylephrine administration (phase 1).</p><br>